Ralpancizumab is a highly specialized humanized monoclonal antibody target the human proprotein convertase subtilisin/kexin type 9 with exceptional binding affinity and selectivity, inhibition of the interaction between PCSK9 and the low-density lipoprotein receptor across various preclinical experimental models to enhance the clearance of cholesterol from the systemic circulation during strictly monitored laboratory observation periods.